TheraRadar
← Back
Data updated: May 30, 2026

GLENMARK PHARMS LTD

Generics

GLENMARK PHARMS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.

2005
Since
145
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
2 Small Molecules

GLENMARK PHARMS LTD's Key Drugs

GLENMARK PHARMS LTD's core commercial portfolio centers on HAILEY 24 FE, ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, NORGESTIMATE; ETHINYL ESTRADIOL, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

GLENMARK PHARMS LTD's Therapeutic Areas

GLENMARK PHARMS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 37%
13 drugs
Neurology 23%
8 drugs
Dermatology 17%
6 drugs
Oncology 14%
5 drugs
Gastroenterology 9%
3 drugs

GLENMARK PHARMS LTD's Top Competitors

GLENMARK PHARMS LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, COSETTE, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GLENMARK PHARMS LTD Pipeline Snapshot

Active clinical trials for GLENMARK PHARMS LTD across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • HAILEY 24 FE leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling